A Study With OPTIVATE® in People With Von Willebrand Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is to assess the pharmacokinetics of OPTIVATE® after a single dose of 80 IU/kg VWF:RCo. The secondary objectives of the study are to assess efficacy and safety of OPTIVATE® in long-term use over at least 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optivate in People With Von Willebrand Disease Undergoing Surgery

NCT00404300

Von Willebrand Disease

TERMINATED PHASE3

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

NCT02246881

Von Willebrand Disease

COMPLETED PHASE3

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

NCT02250508

vonWillebrand's Disease

COMPLETED PHASE2

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

NCT01410227

Von Willebrand Disease

COMPLETED PHASE3

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

NCT00816660

Von Willebrand Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Von Willebrand Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optivate

Plasma-derived Factor VIII

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have given written informed consent.
2. Be aged 12 years or older.
3. Have severe VWD (VWF:RCo \<20%) of known type. Severity will be confirmed by a current VWF:RCo result of \<20%.
4. Be known or expected to require a concentrate for management of VWD.
5. Must have had at least one bleed in the last 12 months which required treatment with a FVIII and VWF concentrate.
6. Have a known lack of, or poor response to, DDAVP.
7. Have a prothrombin time (PT) of not more than 3 seconds above the upper limit of the reference range.
8. At the Baseline Visit (Visit 1), patients must have had at least 5 days since their last infusion of replacement factor concentrate or DDAVP.
9. Female patients of child-bearing potential must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female patient is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. Female patients must not be lactating.

Exclusion Criteria

1. Have a history of inhibitor development to VWF or FVIII or a positive result at screening.
2. Actively bleeding (Note: the patient can enter the study once the bleed is controlled).
3. Presence of major systemic illnesses: renal disease, liver disease, or neurological or psychiatric disease which would compromise the outcome of the study in the opinion of the investigator.
4. Known or suspected hypersensitivity to investigational medicinal product (IMP) or its excipients.
5. Have a recent history of alcohol or drug abuse.
6. Administration of a new chemical entity within the 4 months preceding enrolment.
7. Participation in any other clinical study in which investigational or marketed drugs were employed in the 30 days preceding enrolment into this study, with the exception of the BPL clinical study Protocol 8VWF03.
8. In the opinion of the investigator, the patient is unlikely to comply with the study protocol.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No